'Ang ii' presentation slideshows

Nephroprotection: Actual perspective of ACE inhibitor therapy Piero Ruggenenti

Nephroprotection: Actual perspective of ACE inhibitor therapy Piero Ruggenenti Mario Negri Institute for Pharmacological Research Bergamo, Italy Malaga, October 10, 2005. 1,800,000 patients with ESRD. J. Weening, G. Remuzzi, Lancet, 2005. 90 %. DIALYSIS POPULATION. GLOBAL MAINTENANCE.

838 views • 49 slides

Practical Approaches to Managing Hypertension: Reducing Global Cardiovascular Risk

Practical Approaches to Managing Hypertension: Reducing Global Cardiovascular Risk. Kenneth A. Jamerson, MD Professor of Internal Medicine University of Michigan Medical Director Program for Multicultural Health University of Michigan Health Systems Ann Arbor, Michigan. ?. Key Question.

562 views • 45 slides

Intro. To Cardiovascular Pharmacology

Intro. To Cardiovascular Pharmacology. Vasoactive Peptides & Inhibitors Dec. 2008. Introduction. Cardiovascular Reflex Regulation Overall coordination and integration of the CVS is accomplished primarily by the ANS. Major aspects of CV regulation: BP = CO x TPR

1.43k views • 43 slides

Departmental Student Presentation Steven A. Moore Jr.

Departmental Student Presentation Steven A. Moore Jr. Identification of Amino Acid Motifs in the Human Angiotensin II Type-2 Receptor Involved in G-protein Activation Honors Biology Presentation 2002 Weyhenmeyer Laboratory Dept. of Cell and Structural Biology University of Illinois

538 views • 43 slides

??? ??????? ???????????

??? ??????? ???????????. ????????????. ??????? ?????? ???????. *. ???. ????. ???. *. *. *. ??. ???????? --- ??. ????. ???????????. ?????? ????. ???. ???. ????. ???. ???? Ca 2+. (1). ????. ? ? ? ?. ?? ??. ???????. (1). ??????. ?????????. ????. ???? ??? ??????

804 views • 36 slides

691 views • 34 slides

510 views • 34 slides

New Feature of NCEP ATP III:* Identification of the Metabolic Syndrome

788 views • 30 slides

Losartan: An Attempt at Fighting Heart Failure

Losartan: An Attempt at Fighting Heart Failure. By: Jennifer DeLaet Biochemistry/Molecular Biology Seminar University of Wisconsin-Eau Claire March 29, 1999. Topics of Discussion. Heart Failure Hypertension The Angiotensin system and how it causes hypertension

406 views • 23 slides

Losartan: An Attempt at Fighting Heart Failure

Losartan: An Attempt at Fighting Heart Failure. By: Jennifer DeLaet Biochemistry/Molecular Biology Seminar University of Wisconsin-Eau Claire March 29, 1999. Topics of Discussion. Heart Failure Hypertension The Angiotensin system and how it causes hypertension

316 views • 23 slides

Losartan: An Attempt at Fighting Heart Failure

Losartan: An Attempt at Fighting Heart Failure. By: Jennifer DeLaet Biochemistry/Molecular Biology Seminar University of Wisconsin-Eau Claire March 29, 1999. Topics of Discussion. Heart Failure Hypertension The Angiotensin system and how it causes hypertension

354 views • 23 slides

Critical Role of RAAS in Vasculoprotection: New Science

501 views • 20 slides

Critical Role of RAAS in Vasculoprotection: New Science

381 views • 20 slides

INTRODUCTION TO AUTONOMIC PHARMACOLOGY: Part III Mechanism of neurotransmission at in the autonomic nervous system

INTRODUCTION TO AUTONOMIC PHARMACOLOGY: Part III Mechanism of neurotransmission at in the autonomic nervous system. General Features of Peripheral Autonomic Neurotransmission. NT = Neurotransmitter. General Features of Peripheral Autonomic Neurotransmission.

392 views • 16 slides

Targeting the Renin Angiotensin System: Past, Present and Future

348 views • 14 slides

Ang II (+)

218 views • 6 slides

Effects of Renin System Inhibitors on the Renin System

Effects of Renin System Inhibitors on the Renin System. DRI. Angiotensinogen. Ang I. Non ACE pathways. Renin. ACE. ACEIs. Feedback loop. Ang II. ARBs. AT 1. Receptor.

193 views • 2 slides

Supplemental Figure 1

Supplemental Figure 1. a. b. d. c. *. e. f. g.

72 views • 2 slides

pERK1/2

A. pERK1/2. ERK1/2. ?. 2.0. 1.5. ERK 1/2 phosphorylation (fold). 1.0. 0.5. 0. 137.5. 137.5 +Ang II. 137.5. 137.5 +Ang II. mmol/L. HMA (30 ? mol/L). B. ?. 2.0. 1.5. [ 3 H]- thymidine incorporation (fold). 1.0. 0.5. 0. 137.5. 137.5 +Ang II. 137.5. 137.5 +Ang II.

188 views • 2 slides

pNHE-1

IP: pSer 14-3-3. pNHE-1. pSer 14-3-3. ?. ?. 2.0. 1.5. NHE-1 phosphorylation (fold). 1.0. 0.5. 0. 137.5 +Ang II. 140 +Ang II. mmol/L. 137.5. 140. Supplementary Figure 2.

108 views • 1 slides